-
Circular of Chongqing Municipal Administration for Market Regulation on the Fourth Batch of Food Safety Sampling Inspection of "You Order Me Inspection" (No. 45 of 2022
Time of Update: 2022-12-29
In accordance with the requirements of the Chongqing Municipal Administration for Market Regulation's Notice on Carrying out the 2022 Food Safety "You Point Me Inspection" and "You Send Me for Inspection" Activities, our bureau organized and carried out the "You Point Me Inspection" food safety special sampling activities throughout the city.
-
New anti-cancer compounds are introduced
Time of Update: 2022-11-05
Chemical Communications, 2022; 58 (73): 10237 A team of researchers at the University of Kentucky's Markey Cancer Center has developed a new compound that promises to be a potential anti-cancer therapy to treat aggressive tumors.
-
【CDE Acceptance Fact Sheet】An overview of CDE acceptance from September 12 to September 18
Time of Update: 2022-10-02
The status of acceptance of the consistency evaluation is as follows: There are 29 acceptance numbers for Class 1 drugs, including 23 chemical drugs and 6 therapeutic biological products.
-
Kangyuan Pharmaceutical focuses on the research and development of new drugs, and the price of raw materials such as Zhejiang shellfish has increased
Time of Update: 2022-09-30
Table 1: List of exclusive products of Kangyuan Pharmaceutical According to Intranet data, in 2021, the sales of apricot shell cough granules in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 90 million yuan, an increase of 61.
-
CDMO head companies have struck! Big acquisitions, building bases, building platforms
Time of Update: 2022-09-30
CDMO is one of the segments of CXO and a hot and booming track in recent years, with its business mainly helping innovative drug companies produce and manufacture new drugs. In recent years, with the
-
PNAS: Chromatin dynamics promote DNA repair
Time of Update: 2022-09-07
Original text retrievalDNA damage reduces heterogeneity and coherence of chromatin motions Chromatin is involved in many cellular processes, including DNA replication, transcription, and repair .
Original text retrievalDNA damage reduces heterogeneity and coherence of chromatin motions Chromatin is involved in many cellular processes, including DNA replication, transcription, and repair .
-
Norfloxacin, enrofloxacin aquaculture use specification
Time of Update: 2022-08-19
norfloxacin norfloxacin enrofloxacin enrofloxacinThis standard applies to the treatment of bacterial septicemia, enteritis, red skin disease, printing disease, leukoderma, white-headed and white-mouth disease, gill rot and other related bacterial diseases in aquaculture .
-
The two vice presidents of Guang Yuyuan resigned
Time of Update: 2022-08-15
. The Shanghai Stock Exchange pointed out in the question that Guangyuyuan's sales expenses in 2021 will be 782 million yuan, an increase of 546 million yuan compared with the 2021 semi-annual report, and a year-on-year increase of 35.
-
Arkuda develops potential 'first-in-class' therapy for common Alzheimer's disease
Time of Update: 2022-05-02
Retrieved February 10, 2022, from https:// 64m-to-test-drug-frontotemporal-dementia-2023[2] ARKUDA THERAPEUTICS RAISES $64 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF PROGRAMS TARGETING LYSOSOMAL BIOLOGY TO TREAT NEURODEGENERATIVE DISEASES.
Retrieved February 10, 2022, from https:// -million-series-b-financing-to-advance-pipeline-of-programs-targeting-lysosomal-biology-to-treat-neurodegenerative-diseases/(Original abridged)
-
Kelun Pharmaceutical Holdings subsidiary SKB378/HBM9378 injection obtained clinical trial notice
Time of Update: 2022-05-02
On February 21, Kelun Pharmaceutical issued an announcement saying that the SKB378/HBM9378 injection jointly developed by its holding subsidiary Kelun Botai and Hebo Pharmaceutical obtained the clinical trial notice from the State Drug Administration, agreeing to carry out moderate-to-severe clinical trials for this product.
-
Lei Zuhai's research group and Zhang Fan's group from the Department of Chemistry have made progress in the field of near-infrared second region in vivo biosensing
Time of Update: 2022-01-27
png" cropright="13141f"> Figure 1 Design strategy, response mechanism, spectral changes before and after response, and in vivo sensing imaging of dual-activation probe PN910 Recently, young researcher Lei Zuhai and Professor Zhang Fan created a series of new NIR-II fluorescent dyes Chrodol by replacing the symmetric structure similar to rhodamine in the CX series of dyes with an asymmetric structure similar to Rhodol .
-
Announcement of the Chongqing Municipal Administration of Market Supervision on the Fifth Batch of Food Safety Sampling Inspections (No. 74 of 2021
Time of Update: 2022-01-08
The results of the fifth phase of the "you point me check" random inspection are now announced as follows: The total sampling catering food, roasted food and Caine fruit products , starch and starch products , spices , soy products , pastry , wine , food processed products, meat , sugar , edible agricultural products , edible oils , fats and their products, 167 batches of samples of 15 types of food including vegetable products, confectionery products, and beverages .
-
9 drugs facing 4.1 patent challenges under China's drug patent linkage system
Time of Update: 2022-01-03
If the patentee or interested parties have objections to the four types of patent declarations, they may, within 45 days from the date of publication of the drug marketing authorization application by the National Drug Evaluation Agency, determine whether the relevant technical solutions for the listed drugs fall within the protection scope of the relevant patent rights File a lawsuit with the people's court or request an administrative ruling from the patent administration department of the State Council .
-
EULAR definition: refractory rheumatoid arthritis
Time of Update: 2021-12-04
A EULAR working group was established to come up with comprehensive recommendations for addressing unmet needs in the management of refractory (D2T) RAIn the current literature, different terms are used to describe this subgroup of RA patients, for example, severe, refractory, resistant to multiple drugs or treatments, established and difficult to treat .
-
Capital scrambles to lay out, digital therapy becomes "new medical outlet
Time of Update: 2021-10-11
It is reported that in China, although digital therapy started relatively late, it has developed very rapidly.
For example, Shangyi Technology, which developed the first digital therapy app in China .
